Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHLNASDAQ:MIRONASDAQ:SURFNASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$1.48$1.48$0.63▼$1.51$60.83M1.25664,725 shsN/AMIROMiromatrix Medical$3.39$3.38$0.91▼$4.35$92.95M0.0180,095 shsN/ASURFSurface Oncology$1.07$1.01$0.56▼$1.43$65.08M1.75430,375 shsN/ATARAProtara Therapeutics$3.05+2.3%$3.41$1.60▼$10.48$117.67M1.34773,172 shs321,242 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics0.00%0.00%0.00%0.00%+73.30%MIROMiromatrix Medical0.00%0.00%0.00%0.00%0.00%SURFSurface Oncology0.00%0.00%0.00%0.00%0.00%TARAProtara Therapeutics0.00%-2.87%-2.56%-35.11%+34.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHLAchilles TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/AN/AN/AN/AN/AN/AN/ASURFSurface OncologyN/AN/AN/AN/AN/AN/AN/AN/ATARAProtara Therapeutics2.0638 of 5 stars3.62.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHLAchilles Therapeutics 0.00N/AN/AN/AMIROMiromatrix Medical 0.00N/AN/AN/ASURFSurface Oncology 0.00N/AN/AN/ATARAProtara Therapeutics 3.14Buy$20.50572.13% UpsideCurrent Analyst Ratings BreakdownLatest SURF, TARA, MIRO, and ACHL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025TARAProtara TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$21.004/28/2025TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/16/2025TARAProtara TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$12.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHLAchilles TherapeuticsN/AN/AN/AN/A$3.49 per shareN/AMIROMiromatrix Medical$958.03K97.02N/AN/A$1.25 per share2.71SURFSurface Oncology$30M2.17N/AN/A$0.81 per share1.32TARAProtara TherapeuticsN/AN/AN/AN/A$4.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHLAchilles Therapeutics-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%8/12/2025 (Estimated)MIROMiromatrix Medical-$29.96M-$1.14N/A∞N/A-2,861.17%-120.49%-90.70%N/ASURFSurface Oncology-$63.59M-$1.53N/AN/AN/AN/A-107.81%-65.57%N/ATARAProtara Therapeutics-$44.60M-$1.72N/AN/AN/AN/A-36.37%-33.29%8/5/2025 (Estimated)Latest SURF, TARA, MIRO, and ACHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TARAProtara Therapeutics-$0.47-$0.29+$0.18-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHLAchilles TherapeuticsN/AN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/AN/AN/AN/ASURFSurface OncologyN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHLAchilles TherapeuticsN/A6.046.04MIROMiromatrix Medical0.023.463.46SURFSurface OncologyN/A3.603.60TARAProtara TherapeuticsN/A18.0318.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHLAchilles Therapeutics56.38%MIROMiromatrix Medical29.38%SURFSurface Oncology37.21%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipACHLAchilles Therapeutics5.38%MIROMiromatrix Medical5.20%SURFSurface Oncology12.00%TARAProtara Therapeutics12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHLAchilles Therapeutics25041.10 million38.89 millionNot OptionableMIROMiromatrix Medical7627.42 million25.99 millionOptionableSURFSurface Oncology3560.82 million53.53 millionNot OptionableTARAProtara Therapeutics3038.58 million33.76 millionOptionableSURF, TARA, MIRO, and ACHL HeadlinesRecent News About These CompaniesProtara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025June 14, 2025 | seekingalpha.comTwo Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)June 14, 2025 | marketbeat.comAnalysts Set Expectations for TARA FY2026 EarningsJune 10, 2025 | marketbeat.comChutes & Ladders—Protara gears up for next steps with commercial proJune 7, 2025 | fiercebiotech.comProtara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DEJune 7, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by AnalystsJune 5, 2025 | marketbeat.comThe Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and moreJune 4, 2025 | mmm-online.comProtara Therapeutics names new Chief Commercial OfficerJune 4, 2025 | investing.comMillennium Management LLC Purchases 357,051 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)June 3, 2025 | marketbeat.comProtara Therapeutics Announces Appointment of William Conkling as Chief Commercial OfficerJune 2, 2025 | globenewswire.comToronto Dominion Bank Acquires New Stake in Protara Therapeutics, Inc. (NASDAQ:TARA)May 30, 2025 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Earns Buy Rating from Analysts at Jones TradingMay 24, 2025 | marketbeat.comBNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA)May 24, 2025 | marketbeat.comJones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy RecommendationMay 23, 2025 | msn.comToronto Dominion Bank Takes Position in Protara Therapeutics, Inc. (NASDAQ:TARA)May 23, 2025 | marketbeat.comRichard Levy Spends US$64k On Protara Therapeutics StockMay 22, 2025 | finance.yahoo.comWith 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backingMay 16, 2025 | finance.yahoo.comProtara Therapeutics to Participate in Upcoming Investor ConferencesMay 13, 2025 | globenewswire.comProtara Therapeutics Reports Q1 2025 Financial ResultsMay 11, 2025 | tipranks.comProtara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comHow Protara Therapeutics Reflects Shifts Among Nasdaq Companies by Market CapMay 3, 2025 | kalkinemedia.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSURF, TARA, MIRO, and ACHL Company DescriptionsAchilles Therapeutics NASDAQ:ACHL$1.48 0.00 (0.00%) As of 03/26/2025Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Miromatrix Medical NASDAQ:MIROMiromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.Surface Oncology NASDAQ:SURFSurface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.Protara Therapeutics NASDAQ:TARA$3.05 +0.07 (+2.35%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.06 +0.01 (+0.16%) As of 06/20/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
